Articles On Race Oncology (ASX:RAC)

Bisantrene and decitabine used together offer significantly improved cancer cell-killing across 143 tumour cell lines than either drug used alone Results support the use of decitabine in combination with bisantrene as a potential new treat...

The S&P/ASX 200 Index (ASX: XJO) is having a tough session on Tuesday. In afternoon trade, the benchmark index is down 0.4% to 7,719.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here's why...

The ASX200 is tracking lower than expected, down nearly a quarter of a per cent. The health care sector is leading intraday gains, up more than 0.5%. Real estate has fallen the most, down around 0.8%, Staples follows closely behind down...

ASX healthcare shares are one of only two market sectors trading in the green at the time of writing. The S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.55% and is the best sector of the day so far. These two ASX healthcare sha...

One of my personal investing mottos is "the market is straight up kooky dooks". Not only did I think of this saying again today, I also felt it fitting that it was paraphrased from a movie – in this case the Disney (NYSE: DIS) animated...

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

S&P/ASX 200 Index (ASX: XJO) stock GUD Holdings Ltd (ASX: GUD) is off to the races on Tuesday. Shares in the diversified automotive market products company closed yesterday trading for $9.77. At the time of writing in late morning tr...

Race Oncology (ASX:RAC) has shared the results from recent preclinical work performed under contract at Oncolines in the Netherlands, combining bisantrene with decitabine.

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...

By Tim Boreham ASX code: Race Oncology ((RAC)) Shares on issue: 164,778,179 Market cap: $237.3m Financials (December half 2023): revenue nil, loss of -$5.66m (-$4.41m deficit previously), cash of $13.7m (down -48%). During the period the co...

What is traditional chemotherapy? How is Race Oncology trying to change it? What are the alternative cancer treatments? Race Oncology (ASX:RAC) chief executive Dr Daniel Tillett joins the Stockhead TV studio to investigate these questions a...

Race Oncology says certificate of analysis issued by Ardena for first cGMP batch of bisantrene formulation RC220 Confirms RC220 meets all cGMP specifications required for a human IV drug product Company says major milestone in the progre...

The ASX200 closed the day down .4 of a per cent, with IT stocks weighing on the market and energy leading the pack with marginal gains at the other end of the spectrum. The Energy sector tipped the field into positive territory, closing...

The ASX 200 slipped by -0.3% on Tuesday, tracking movements on Wall Street overnight.  The local market was dragged down by profit taking in the Tech and Comm Services sectors, while Energy was the only one to close in the green. Advancers...

Race Oncology (ASX: RAC) has made further progress in the development of its proprietary bisantrene formulation drug, RC220 – whereby a Certificate of Analysis (CoA) for the first current Good Manufacturing Practice (cGMP) batch has been is...

Race Oncology (ASX:RAC) has announced that a Certificate of Analysis has been issued for the first current Good Manufacturing Practice batch of its proprietary bisantrene formulation, RC220.

Mineral Resources (MIN) has updated on the Lockyer-5 gas well. The Kingia Sandstone target downhole the Perth Basin asset was successfully hit at 4.2km depth. Wireline logs revealed 27m of net gas pay with porosity of 18%. Shares...

Race Oncology Ltd (ASX: RAC) shares are on form and racing higher on Monday. In afternoon trade, the ASX All Ords share is up over 16% to $1.81. This means that the oncology company's shares are now up an impressive 130% since this time la...

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

Race Oncology appoints Associate Professor Erin Howden to scientific advisory board Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients Appointment aims to bring Race Oncology’s new formulatio...

ASX looks set rise after mixed session on Wall street overnight Momentum in the tech sector wanes; Tesla cops a downgrade Oil prices rise, iron ore under pressure and copper prices surge  The ASX looks set to rise on Thursday morning. The...

It’s been a tough couple of years for ASX health care with challenging economic conditions including steep interest rates rises to combat soaring inflation hitting the sector like a nasty dose of influenza. Furthermore, a frenzy around the...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

The ASX200’s been trading down a quarter of a per cent – even further than expected.  The utilities and financials sectors are in the lead – up around 0.4 of a per cent, while IT is lagging  – down more than 2 per cent. Australia’s Gr...

Atomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key results from Phase 1 study Race Oncology’s drug shows potent anticancer activity    Atomo up 90pc on HIV kit sales Atomo Diagnostics (ASX:AT1)...

Race Oncology reports an apparent step forward in finding treatment for Acute Myeloid Leukemia Race’s bisantrene drug – in combination with decitabine – deemed effective in animal models to treat a type of leukemia Findings pave the...

The ASX200 is set to fall with futures down -0.13% near 8.30am AEDT on Wednesday. The US markets pared recent gains again overnight as the world heads into a week of data. Fed chief Jerome Powell gives testimony in congress tonight Austr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Early detection and effective treatment can lead to remission or cure for many cancers Optiscan’s tech brings surgeons and pathologists together to better diagnose, treat and monitor cancer Race Oncology’s working to minimise cardiovascula...

Leading cardiologist says bisantrene has potential to significantly change cancer treatment landscape Bisantrene could minimise damage to the heart linked to many cancer therapies New CEO is prioritising swift delivery of bisantrene to pat...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

The Lake Resources N.L. (ASX: LKE) share price fell to a new 52-week low of 13 cents on Thursday. The ASX lithium explorer has lost 83% of its share price value since the beginning of 2023. Today's fall follows the annual general meeting...

Australian company Race Oncology (ASX:RAC) has announced the appointment of Dr Daniel Tillett as its new chief executive officer.

Race Oncology appoints former chief scientific officer and executive director Dr Daniel Tillet as CEO Independent chair Mary Harney says RAC now best positioned to deliver on its primary focus of advancing bisantrene Company releases its u...

Dr Daniel Tillett steps into the role of CEO at Race Oncology (ASX:RAC), bringing with him more than 25 years of biotech experience He will work with RAC Executive Director Dr Pete Smith to advance the company’s strategic, clinical, and...

ASX to open slightly lower after a retreat on Wall Street Fed officials said they are open to more rate hikes Nvidia earnings in focus   Aussie shares are poised to slip on Wednesday after US stocks retreated on Wall Street. At 8am AEDT,...

ASX futures were down 0.06 per cent near 8:30 am AEDT, implying the ASX will dip slightly into the red today. The US markets overnight snapped a five-day winning streak, even as Nvidia reported record earnings. The release of the Fed...

Lake Resources N.L. (ASX: LKE) shares had a subdued finish to the week. The lithium developer's shares just closed flat at 16.5 cents. This means that its shares are now down approximately 80% since the start of the year. Can Lake Resource...

The Lake Resources Ltd (ASX: LKE) share price has been under intense pressure over the last year. As a result, the lithium explorer's shares are now a shadow of what they once were, racking up an explosive 92% dumping from their April 2022...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The good news for income investors is that there are a good number of quality ASX dividend stocks to choose from on the Australian share market. But which could be buys next week? Well, two that analysts at Morgans rate highly are listed b...

SYDNEY, Nov. 14, 2023 /PRNewswire/ — HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023. Outgoing CEO Bryce Carmine wil...

The Australian share market is a great place to generate a passive income. And while it may take time to generate life-changing sums of money from ASX shares, that doesn't mean you can't generate income from smaller investments. Furthermor...

The Pro Medicus Ltd (ASX: PME) share price has spiked well above $86 in Monday trading amid investors hearing news of the company's latest contract win. At the time of writing, the ASX healthcare share is trading at $86.66 a share, or 1.74...

ASX shares that have fallen hard but have a compelling future could be good opportunities if they're able to bounce back. I do not believe the outlook is going to be uncertain forever for sectors like retail or real estate. The short term...

The Australian share market is a great place to generate a passive income. That's because it is home to a huge number of ASX shares that reward their shareholders with dividends each year. But which ones could be buys right now? Two passiv...